Biotechnology, vaccines, and public health by Emergent Biosolutions

Emergent Biosolutions announced its commitment to developing, manufacturing, and delivering products aimed at protecting communities globally. The company’s strategy is centered on scientific ...

Emergent Biosolutions announced it has received a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR) to support its ...

Emergent Biosolutions has supplied its medical countermeasures to more than 20 countries, strengthening international efforts to protect public health. The company stated that these deliveries ...

Emergent Biosolutions has announced the donation of thousands of units of NARCAN Nasal Spray throughout the U.S. since 2021. The company referenced its ongoing commitment to social responsibility ...

Emergent Biosolutions is working with governments worldwide to strengthen preparedness for major health threats, including pandemics and bioterrorism. The company focuses on providing solutions ...

Emergent Biosolutions announced it will host a conference call today at 5:00 p.m. Eastern Time to present its financial results for the first quarter of 2026. The call will provide investors and ...

Emergent Biosolutions has announced a strategic manufacturing partnership with Substipharm Biologics to support the production of a Japanese Encephalitis vaccine in the U.S. This collaboration ...

Emergent Biosolutions has reaffirmed its longstanding mission to protect communities from health threats, emphasizing over 25 years of work in this sector. The company stated that its primary ...

Emergent Biosolutions will hold its 2026 annual meeting of stockholders on April 29. Investors are set to vote on a series of important proposals that could impact the company’s direction. ...

Emergent Biosolutions has entered a partnership with British Columbia to provide NARCAN nasal spray as part of the expansion of the province's Take Home Naloxone Program. The agreement aims to ...

Emergent Biosolutions has introduced a new NARCAN Nasal Spray carrying case and multipack options aimed at improving opioid overdose preparedness. The launch is accompanied by a targeted ...

Emergent Biosolutions has announced its Emergent GIVES 2026 Cycle A charitable donations supporting organizations focused on public health, scientific leadership development, and assistance for ...

Emergent Biosolutions has announced the award of a new contract with the U.S. government, focusing on the supply of smallpox medical countermeasures. The company also revealed it has received new ...

Emergent Biosolutions has launched new carrying cases for its NARCAN Nasal Spray, aiming to make it easier for individuals to have the overdose reversal medication accessible when needed. The ...

Emergent Biosolutions has announced it won a series of new contracts and a contract modification with the Public Health Agency of Canada and the Department of National Defence. The agreements are ...

Emergent Biosolutions is marking a significant milestone—10 years since the U.S. Food and Drug Administration's approval of their NARCAN (naloxone HCl) Nasal Spray. This product has been pivotal ...

Emergent Biosolutions is scheduled to host its Q3 earnings call on October 29, where the company plans to present its financial results for the quarter. This event serves as a crucial opportunity ...

Emergent Biosolutions, a key player in the biotech industry, has taken center stage at the World Vaccine Congress in Amsterdam by presenting data on its smallpox vaccine. Mario Rodriguez, the ...